FDA Guidances On Actual Use Studies, Switches Will Clarify Agency Processes
This article was originally published in The Tan Sheet
Executive Summary
A guidance on conducting actual use trials for Rx-to-OTC switch candidates is under development, according to FDA Office of New Drugs Director John Jenkins, MD
You may also be interested in...
Medicare HSAs May Compel Drug Industry To Rethink Position On OTCs
The growth of health savings accounts could force pharmaceutical companies to rethink their approach to OTC switches and consumer marketing, medical economist J.D. Kleinke told the Pharmaceutical Research & Manufacturers of America
Medicare HSAs May Compel Drug Industry To Rethink Position On OTCs
The growth of health savings accounts could force pharmaceutical companies to rethink their approach to OTC switches and consumer marketing, medical economist J.D. Kleinke told the Pharmaceutical Research & Manufacturers of America
Medicare HSAs May Compel Drug Industry To Rethink Position On OTCs
The growth of health savings accounts could force pharmaceutical companies to rethink their approach to OTC switches and consumer marketing, medical economist J.D. Kleinke told the Pharmaceutical Research & Manufacturers of America